NCT05689372View on ClinicalTrials.gov

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.